📊 SLXNW Key Takeaways
Is Silexion Therapeutics Corp (SLXNW) a Good Investment?
Silexion is a pre-commercial stage biotech burning $10.8M annually with minimal revenue ($155K) and only 6-7 months of cash runway remaining. Extreme operating losses ($11.6M) relative to revenue, deteriorating net income trends, and absence of clear commercialization milestones indicate high failure risk without immediate capital infusion.
Why Buy Silexion Therapeutics Corp Stock? SLXNW Key Strengths
- Zero long-term debt provides financial flexibility for future fundraising
- Current ratio of 2.41x ensures short-term operational stability
- Revenue growing 453.6% YoY indicates early market traction despite minimal absolute base
SLXNW Stock Risks: Silexion Therapeutics Corp Investment Risks
- Unsustainable cash burn of $10.8M annually against $6M cash balance = 6-7 month runway
- Operating losses of $11.6M exceed revenue by 75x, indicating pre-commercial or failed product stage
- Deteriorating profitability (net income down 200% YoY) with negative ROE (-457.6%) and ROA (-165.1%)
- Likely imminent dilutive equity raise required to prevent insolvency
- Minimal absolute revenue ($155K) suggests either early clinical trials or commercialization failure
Key Metrics to Watch
- Monthly cash burn rate and updated runway estimate
- Clinical trial progress or regulatory filing milestones
- Revenue trajectory acceleration post-453.6% YoY baseline
- Form 4 insider activity patterns (buying vs. selling)
- Capital raise announcements and dilution impact on equity
Silexion Therapeutics Corp (SLXNW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.41x current ratio provides a solid financial cushion.
SLXNW Profit Margin, ROE & Profitability Analysis
SLXNW vs Healthcare Sector: How Silexion Therapeutics Corp Compares
How Silexion Therapeutics Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Silexion Therapeutics Corp Stock Overvalued? SLXNW Valuation Analysis 2026
Based on fundamental analysis, Silexion Therapeutics Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Silexion Therapeutics Corp Balance Sheet: SLXNW Debt, Cash & Liquidity
SLXNW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Silexion Therapeutics Corp's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $394.94 reflects profitable operations.
SLXNW Revenue Growth, EPS Growth & YoY Performance
Silexion Therapeutics Corp Dividends, Buybacks & Capital Allocation
SLXNW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Silexion Therapeutics Corp (CIK: 0002022416)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SLXNW
What is the AI rating for SLXNW?
Silexion Therapeutics Corp (SLXNW) has an AI rating of STRONG SELL with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SLXNW's key strengths?
Claude: Zero long-term debt provides financial flexibility for future fundraising. Current ratio of 2.41x ensures short-term operational stability.
What are the risks of investing in SLXNW?
Claude: Unsustainable cash burn of $10.8M annually against $6M cash balance = 6-7 month runway. Operating losses of $11.6M exceed revenue by 75x, indicating pre-commercial or failed product stage.
What is SLXNW's revenue and growth?
Silexion Therapeutics Corp reported revenue of $155.0K.
Does SLXNW pay dividends?
Silexion Therapeutics Corp does not currently pay dividends.
Where can I find SLXNW SEC filings?
Official SEC filings for Silexion Therapeutics Corp (CIK: 0002022416) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SLXNW's EPS?
Silexion Therapeutics Corp has a diluted EPS of $8.96.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SLXNW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Silexion Therapeutics Corp has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SLXNW stock overvalued or undervalued?
Valuation metrics for SLXNW: ROE of -457.6% (sector avg: 15%), net margin of -7,685.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SLXNW stock in 2026?
Our dual AI analysis gives Silexion Therapeutics Corp a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SLXNW's free cash flow?
Silexion Therapeutics Corp's operating cash flow is $-10.8M, with capital expenditures of $9.0K. FCF margin is -6,985.8%.
How does SLXNW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -7,685.2% (avg: 12%), ROE -457.6% (avg: 15%), current ratio 2.41 (avg: 2).